The current dogma garnered from mouse tumour models proposes that DC ingestion of tumour DNA, or use of STING agonist therapy, leads to STING-dependent IFN-β production that enhances conventional (c) DC function to boost subsequent anti-tumour immune responses (15, 24). The gene discussed is STING1; the disease is neoplasm.